Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Sofi-cel is an investigational, potential first-in-class, allogeneic, anti-CD7 CAR-T cell therapy currently under evaluation in a pivotal trial (T-RRex) for patients with relapsed or refractory (R/R) ...

Crispr Therapeutics AG ( ($CRSP) ) has risen by 9.03%. Read on to learn why. Crispr Therapeutics AG has seen its stock price rise by 9.03% over ...

From custom gene editing to a discovery that could help stop pancreatic cancer before it starts, these advances offer a ...

Biotech startup CrisprBits uses CRISPR-based techniques to change the shape of diagnostics by decoding genetic sequencing ...

The gene editing market is experiencing significant growth, with a projected annual growth rate (CAGR) of 16-18% in the coming years. This expansion is fueled by breakthroughs in gene-editing ...

Exa-cel could provide benefit before kids develop chronic organ damage ...

By stripping two metabolic enzymes, scientists created a mycoprotein that needs less energy, emits less carbon, and rivals ...

CRISPR Therapeutics (NASDAQ:CRSP) gains visibility as biotechnology activity aligns with broader movements across the Nasdaq ...

Only a couple of years since the first sickle cell disease (SCD) gene therapies gained U.S. FDA approval, researchers are working to expand access for younger children, and to improve manufacturing ...

The "Mice Model Market - Global Forecast 2025-2032" has been added to ResearchAndMarkets.com's offering. The mice model market is experiencing robust growth, with projected expansion from USD 1.61 ...

New gene-editing tools – most notably the Nobel Prize-winning CRISPR-Cas9 – allow targeted tweaks to a crop’s genome, ...